Albany, NY -- (SBWire) -- 01/15/2019 --Global Radiopharmaceuticals Market: Report Analyst's Estimations

Since the first radiopharmaceutical that was commercialized way back in 1950, Iodine-131 human serum albumin (RISA), the concept of nuclear medicine has been harnessed consistently over the past half a century. And, the future of the healthcare industry substantially depends on radiopharmaceuticals too, for both diagnostic and therapeutic applications. Radiopharmacology is useful several branches of medicine including cardiology, nephrology, oncology, gastroenterology, immunology, and neurology. As per the evaluations of this business intelligence study, the demand in the global radiopharmaceuticals market will increment at a steady CAGR of 5.4% during the forecast period of 2017 to 2024. Revenue-wise, the global radiopharmaceuticals market is estimated to attain a value of US$7,430.8 million by 2024, mounting from its calculated worth of US$5,145.1 million as of 2017.

Obtain Report Details @

https://www.transparencymarketresearch.com/radiopharmaceuticals-market.html

The strong prevalence of cancer and cardiovascular diseases, growing awareness regarding its positive effects, increasing preference of SPECT and PET scans, and advancements in radiotracers are some of the key drivers of the radiopharmaceuticals market. On the other hand, factors such as stringent regulatory guidelines, supply shortage of radioisotopes, and short half-life of radiopharmaceuticals are hindering the market from flourishing.

Technetium-99 Identified as Key Radioisotope Segment

On the basis of radioisotope, the radiopharmaceutical market has been segmented into Gallium-67, Technetium-99, Rubidium-82, 18F, Iodine-123, Lutetium-177, and Yttrium-90. Among these, the Technetium-99 segment continues to be the one with maximum demand, generating a revenue of US$2,582.6 million in 2017. Technetium-99 is the most widely used radioisotope in nuclear medicine and nearly 70% to 80% of it is being used as a diagnostic nuclear medicine. Technetium-99 is a short-lived radioisotope (half-life of 6 hours) when produced from molybdenum-99 inside a nuclear reactor.

Request Report Brochure @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=213

On the other hand, the 18F radioisotope segment of the radiopharmaceutical market has been highlighted as the one with above-average CAGR of 5.7% during the period of 2017 to 2024. 18F is a positron emitting radioisotope produced in a cyclotron. 18F is used for positron emission tomography (PET) in order to detect various types of cancer. Increasing demand for 18F-FDG has advanced technological development in accelerator technology, radiochemistry, automated processing modules, detector systems, and imaging software.

Enquiry for Discount on this Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=213

About Transparency Market Research
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com